Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Preliminary Diagnostic Performance of [68Ga]-NeoBOMB1 in Adult Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

NCT03724253 is registered in ClinicalTrials.gov with Advanced Accelerator Applications as lead sponsor.

NCT NCT03724253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03724253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Preliminary Diagnostic Performance of [68Ga]-NeoBOMB1 in Adult Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
Lead sponsor
Advanced Accelerator Applications
Phase
Phase 2
Overall status
Terminated
Start date
July 3, 2018
Completion date
July 5, 2019
Enrollment
19 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, non small cell lung cancer, prostate cancer, small cell lung cancer